Maze Therapeutics Inc. (MAZE)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's success and planned pivotal trial initiation.
Maze Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 10 | $259 | $291.4 | $32.4 | 12.51% |
 Farallon Capital Farallon Capital Management LLC | 373,000 | $11.13M | $10.89M | -$246,553 | -2.21% |
| BG Bart Gancher Intech Investment Management LLC | 9,523 | $358,871.49 | $277,595.45 | -$81,276.04 | -22.65% |
 David Kim Paradigm Biocapital Advisors LP | 2.74M | $81.92M | $79.72M | -$2.2M | -2.69% |
| NM Nir Messafi Deep Track Capita LLP | 3.48M | $48.2M | $101.01M | $52.82M | 109.59% |
Maze Therapeutics Inc. (MAZE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Maze Therapeutics Inc. ever had a stock split?
Maze Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jason Coloma CEO | NASDAQ (NMS) Exchange | 578784100 CUSIP |
| US Country | 141 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Maze Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development of small molecule precision medicines targeted at treating renal, cardiovascular, related metabolic diseases, and obesity in the United States. Established in 2017 and based in South San Francisco, California, Maze Therapeutics was formerly known as Modulus Therapeutics, Inc., a name change that occurred in September 2018. The company is actively advancing its clinical programs, aiming to address significant unmet needs in the healthcare landscape.
Products and Services
- MZE829 – MZE829 is an oral small molecule inhibitor specifically designed to target apolipoprotein L1. Currently, it is in Phase II clinical trials aimed at treating patients suffering from APOL1 kidney disease. This innovative approach seeks to improve renal function and overall patient outcomes.
- MZE782 – MZE782 is another oral small molecule inhibitor, but it focuses on inhibiting the solute transporter SLC6A19. The product is in Phase I clinical trials, and it is intended for use in treating chronic kidney disease. This therapy represents a step forward in addressing the challenges faced by patients with degenerative kidney conditions.
